Pharmaceutical Company Patient Advisory Board: Advanced Systemic Mastocytosis

Jul 16, 2019

We at TMS strive to keep patients and families informed of opportunities that may help lead to improvements of quality of life for individuals affected by mast cell disease. With that in mind, we are sometimes able to offer opportunities to share your experiences related to your or a loved one’s disease. Immediately prior to our 2019 TMS Patient & Caregiver Conference in May 2019 in Foster City-San Mateo, California, the pharmaceutical company, Blueprint Medicines, held a 4-hour meeting with several patients with advanced systemic mastocytosis (SM). This patient advisory board helped researchers from the company gain insights into the advanced SM experience of patients to better understand challenges and decision points from the patient perspective. Partnering with those working to improve the lives of patients with mast cell disease is a key area of focus for TMS.